title: Acute effects of progesterone and the antiprogestin RU 486 on gonadotropin secretion in the follicular phase of the menstrual cycle.
abstract: Considerable controversy still exists concerning the role of progesterone in the initiation of the midcycle gonadotropin surge in humans. We, therefore, carried out a prospective randomized study to determine the potential of progesterone to initiate a gonadotropin surge and the acute effects of a potent progesterone antagonist (RU 486) on follicular phase gonadotropin secretion in normal women. The women underwent frequent blood sampling for 4 in the midfollicular (day 6) or late follicular phase (day 10). They then received either progesterone (10 mg, im) or RU 486 (10 or 100 mg, orally), and blood sampling was continued for an additional 8 h. Four women received each of the drug regimens in the early follicular phase, and four received each regimen in the late follicular phase. Two additional women were studied as control subjects at each stage of the cycle. Progesterone administration in the mid- and late follicular phases resulted in an acute increase in plasma LH and FSH concentrations, and the increases correlated with the base line plasma estradiol concentrations (P less than 0.05). In contrast to progesterone, the women who received RU 486 in the mid- and late follicular phases had a reduction in plasma LH and FSH concentrations after drug administration. The response in the mid-follicular phase was considerably less than that in the late follicular phase, and the extent of the response correlated with the baseline plasma estradiol concentrations (P less than 0.005). The changes were similar in response to both RU 486 doses. We conclude that progesterone can initiate a gonadotropin surge in the late follicular phase of the menstrual cycle. The inhibitory effect of the progesterone antagonist RU 486 suggests that a positive feedback mechanism involving progesterone may be influential some time before the surge onset.
authors.affiliation: Harris Birthright Centre for Reproductive Biology, Sheffield, United Kingdom.
authors.forename: J M
authors.initials: JM
authors.lastname: Permezel
authors.forename: E A
authors.initials: EA
authors.lastname: Lenton
authors.forename: I
authors.initials: I
authors.lastname: Roberts
authors.forename: I D
authors.initials: ID
authors.lastname: Cooke
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D004963:Estrenes / Q000494:pharmacology*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005498:Follicular Phase / Q000187:drug effects*; D006062:Gonadotropins / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D015735:Mifepristone; D011374:Progesterone / Q000494:pharmacology*; D011897:Random Allocation
chemical_list: D004963:Estrenes; D006062:Gonadotropins; D015735:Mifepristone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone